1. Home
  2. BGLC vs ICU Comparison

BGLC vs ICU Comparison

Compare BGLC & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BGLC
  • ICU
  • Stock Information
  • Founded
  • BGLC 2017
  • ICU 2018
  • Country
  • BGLC Malaysia
  • ICU United States
  • Employees
  • BGLC N/A
  • ICU N/A
  • Industry
  • BGLC Medical Specialities
  • ICU Biotechnology: Pharmaceutical Preparations
  • Sector
  • BGLC Health Care
  • ICU Health Care
  • Exchange
  • BGLC Nasdaq
  • ICU Nasdaq
  • Market Cap
  • BGLC 10.7M
  • ICU 10.4M
  • IPO Year
  • BGLC N/A
  • ICU N/A
  • Fundamental
  • Price
  • BGLC $5.14
  • ICU $0.71
  • Analyst Decision
  • BGLC
  • ICU
  • Analyst Count
  • BGLC 0
  • ICU 0
  • Target Price
  • BGLC N/A
  • ICU N/A
  • AVG Volume (30 Days)
  • BGLC 3.1M
  • ICU 19.6M
  • Earning Date
  • BGLC 08-13-2025
  • ICU 08-12-2025
  • Dividend Yield
  • BGLC N/A
  • ICU N/A
  • EPS Growth
  • BGLC N/A
  • ICU N/A
  • EPS
  • BGLC N/A
  • ICU N/A
  • Revenue
  • BGLC $9,265,870.00
  • ICU $428,000.00
  • Revenue This Year
  • BGLC N/A
  • ICU $754.07
  • Revenue Next Year
  • BGLC N/A
  • ICU $100.09
  • P/E Ratio
  • BGLC N/A
  • ICU N/A
  • Revenue Growth
  • BGLC N/A
  • ICU N/A
  • 52 Week Low
  • BGLC $2.01
  • ICU $0.31
  • 52 Week High
  • BGLC $15.60
  • ICU $9.56
  • Technical
  • Relative Strength Index (RSI)
  • BGLC 55.54
  • ICU 49.31
  • Support Level
  • BGLC $3.57
  • ICU $0.51
  • Resistance Level
  • BGLC $7.05
  • ICU $0.62
  • Average True Range (ATR)
  • BGLC 1.44
  • ICU 0.11
  • MACD
  • BGLC -0.04
  • ICU 0.04
  • Stochastic Oscillator
  • BGLC 25.00
  • ICU 60.90

About BGLC BioNexus Gene Lab Corp Common stock

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About ICU SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Share on Social Networks: